Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis
Rifaximin monotherapy demonstrated superior efficacy, safety, and tolerability compared to lactulose for preventing HE recurrence among patients with cirrhosis in a multi-center setting. These findings support rifaximin as a more effective long-term therapeutic option for secondary prophylaxis of HE.
Authors
- Abdullah Elrefae (ORCID: https://orcid.org/0000-0002-3739-4045)
- Awais Mustafa
- Jazba Yousaf
- Monther Qandeel (ORCID: https://orcid.org/0000-0002-7176-4214)
- Ali Asghar (ORCID: https://orcid.org/0009-0009-3746-2931)
- Maryam Atta
- Shoukat Hussain
- Aima Tahir
- Muhammad Iftikhar Khattak
- Hifza Ishtiaq
Institutions
- Mayo Clinic (US)
- University of Azad Jammu and Kashmir (PK)
- Punjab Medical College (PK)
- Dudley Group NHS Foundation Trust (GB)
- Capital University of Science and Technology (PK)
- Mayo Clinic in Arizona (US)
- Central Middlesex Hospital (GB)
- Mayo Clinic in Florida (US)
- Jos University Teaching Hospital (NG)
- Health Services Academy (PK)
- Institute of Medical Sciences (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-27
- DOI
- https://doi.org/10.7759/cureus.95519
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00